Why It Matters

The Center for Addiction Science, Policy and Research (CASPR) ended its lobbying contract with Tenagrity Solutions LLC in a termination filing signed Friday, July 24. The contract closed just as the organization's federal agenda had widened from addiction medicine into prediction-market regulation.

By The Numbers

The termination reports no lobbying income for quarter three of 2026, the end of a steady decline. Tenagrity reported $20,000 from CASPR in quarter one of 2026 and $10,000 in quarter two, down from $30,000 and $20,000 in the corresponding quarters of 2025. Legis1 puts CASPR's total lobbying expenditure at $130,000 across five years. Caroline DeBerry, Tenagrity's founder and chief executive officer, was the sole lobbyist on every filing.

Broader Context

CASPR's core agenda held steady across the contract. The organization lobbied Congressional offices and U.S. Department of Health and Human Services (HHS) officials on expanding glucagon-like peptide-1 (GLP-1) access as a substance use disorder treatment.

They lobbied U.S. Food and Drug Administration (FDA) for reforms including modernized clinical endpoints for substance use disorder, and on proposed legislation creating a substance use disorder Priority Review Voucher (PRV). By 2026 it had added support for National Institutes of Health trials of repurposed off-patent therapeutics and widely used supplements, and for White House and Center for Medicare and Medicaid Innovation work on non-opioid acute pain therapeutics. Its appropriations asks had moved to fiscal year 2027 Labor-HHS and Agriculture-FDA language, with discussions centered on Rep. Ben Cline (R-VA), Rep. Jake Auchincloss (D-MA), and Rep. Josh Harder (D-CA).

The newer thread ran through gambling. CASPR backed H.R. 7840, the Event Contract Enforcement Act, on the reasoning that event contracts constitute gambling and therefore a common addictive activity. The bill, sponsored by Rep. Blake Moore (R-UT) and Rep. Salud Carbajal (D-CA), would prohibit event contracts tied to war, terrorism, assassination, elections, government conduct, and gaming.

The Bottom Line

The filings describe an organization that was broadening its theory of addiction policy, from pharmaceutical development into the regulation of prediction markets, while its lobbying budget shrank quarter by quarter to nothing. That combination points less to a strategic exit than to a funding limit reached mid-campaign. The immediate test is the fiscal year 2027 appropriations cycle, where the endpoint-modernization and voucher language requests now need a champion inside the House Appropriations Committee rather than a lobbyist working its members from outside.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article